TWIST1 and neoplasm: In a parallel study, similar therapeutic results were observed in a GL261 syngeneic mouse GBM model (Fig. 5, D and E), collectively suggesting that pharmacological inhibition of Twist1 by harmine overcomes tumor resistance to CAR T cell therapy in GBM.